Vivos Therapeutics (VVOS) grants 250K shares, 150K options
Rhea-AI Filing Summary
Vivos Therapeutics, Inc. (VVOS) reported that Principal Accounting Officer Bradford K. Amman received equity awards on July 31, 2026. He was granted 150,000 stock options with an exercise price of $0.41 per share, expiring July 31, 2036, and a separate grant of 250,000 shares of common stock at $0.41 per share. Following these grants, he holds 326,533 stock options and 250,080 shares of common stock directly. The option grant was made under the company’s 2024 Omnibus Equity Incentive Plan and is scheduled to vest at a stated rate of 25,000 shares per month from November 1, 2026 through April 1, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 250,000 shares
Net Buy
2 txns
Insider
Amman Bradford K.
Role
Principal Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 150,000 | $0.41 | $61K |
| Grant/Award | Common Stock | 250,000 | $0.41 | $103K |
Holdings After Transaction:
Stock Option (Right to Buy) — 326,533 shares (Direct);
Common Stock — 250,080 shares (Direct)
Footnotes (1)
- F1. On July 31, 2026 (the "Grant Date"), the Reporting Person received a grant of 150,000 stock options, which grant was made under the Issuer's 2024 Omnibus Equity Incentive Plan. Stock options shall vest and become exercisable at the rate of 25,000 shares per month from November 1, 2026 through April 1, 2026.
Key Figures
Stock options granted: 150,000 options
Option exercise price: $0.41 per share
Option expiration date: July 31, 2036
+4 more
7 metrics
Stock options granted
150,000 options
Grant on July 31, 2026 under 2024 Omnibus Equity Incentive Plan
Option exercise price
$0.41 per share
Exercise price for 150,000 stock options granted July 31, 2026
Option expiration date
July 31, 2036
Expiration date of 150,000 stock options
Common stock granted
250,000 shares
Common stock award on July 31, 2026 at $0.41 per share
Common stock holdings after grant
250,080 shares
Direct common stock ownership following July 31, 2026 grant
Option holdings after grant
326,533 options
Total stock options directly held after July 31, 2026 grant
Monthly vesting amount
25,000 shares per month
Stated vesting rate from November 1, 2026 through April 1, 2026
Key Terms
Stock Option (Right to Buy), Omnibus Equity Incentive Plan, vesting, Principal Accounting Officer
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Omnibus Equity Incentive Plan financial
"made under the Issuer's 2024 Omnibus Equity Incentive Plan"
A single, company-wide plan that lets a business grant different kinds of stock-based pay — such as stock options, shares that vest over time, or other equity awards — to employees, directors and consultants. It matters to investors because it determines how much of the company can be paid out in shares, how quickly those shares enter the market, and how well employees are motivated to grow the business; think of it as a toolbox or menu for paying with ownership stakes that can dilute existing holders and affect company performance.
vesting financial
"Stock options shall vest and become exercisable at the rate of 25,000 shares"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Principal Accounting Officer financial
"officer_title": "Principal Accounting Officer""
The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.
FAQ
What equity awards did VVOS grant to Bradford K. Amman on July 31, 2026?
On July 31, 2026, VVOS granted 150,000 stock options at an exercise price of $0.41 per share and a separate award of 250,000 shares of common stock at $0.41 per share to Principal Accounting Officer Bradford K. Amman.
What are the key terms of Bradford K. Amman’s VVOS stock options?
Bradford K. Amman received 150,000 stock options on July 31, 2026 with an exercise price of $0.41 per share, expiring on July 31, 2036. The options were granted under Vivos Therapeutics’ 2024 Omnibus Equity Incentive Plan and have a stated monthly vesting schedule beginning November 1, 2026.
At what price were Bradford K. Amman’s VVOS equity awards valued?
Both the 150,000 stock options and the 250,000 common shares granted to Bradford K. Amman on July 31, 2026 were reported at $0.41 per share in the Form 4 filing.
Under which plan were the VVOS stock options granted to Bradford K. Amman?
The 150,000 stock options granted to Bradford K. Amman on July 31, 2026 were issued under Vivos Therapeutics, Inc.’s 2024 Omnibus Equity Incentive Plan, according to the Form 4 footnote.
AI-generated analysis. How Rhea-AI works. Not financial advice.
